Replies to post #150592 on Arrayit Corporation (ARYC)

[PennyStock Alert]

Absolutely. This is a long term play, always has been for many of us

[StockDetective]

Once again read this... Arrayit Corp (ARYC) is involved in a huge and rapidly growing IN-NETWORK partnership. IMO everything they do is strategically done & consulted to better position themselves in the market for competitive reasons. Massive nationwide expansion is currently in the works through huge partnerships & TeleMedicine.

As to financials, it appears that the minor setback occurred late 2018.

Looking at the letter to shareholders... “At year end, we implemented a new electronic medical billing solution and we expect to bill $1 million per week for our health and wellness tests.” Insurance billing/coding requires medical auditing, which falls under the AAPC.

Arrayit Corporation Retains Top Credentialing Company to Accelerate Allergy Testing Services Reimbursement from Major Healthcare Payors.

http://arrayit.com/Arrayit_Corporation_ARYC_Corpo/Microarray_Media_-_Press/Arrayit_Corporation_Retains_To/arrayit_corporation_retains_top_credentialing_company_to_acceler.html

The recently released 8K stated RRBB did not issue any audits, which does not mean that no work was done. Therefore, makes me believe that a concurring partner or independent auditors (meaning they can start where RRBB left off) may be finishing up the little work left (end of 2018) to complete the audit of the financials. Many investors here have stated that the company is current internally, which to my understanding means financials are finished (pending audit). The company has stated that they will be releasing all audited financials & quarterly filings at once to go current and list under QB before qualifying to list on the NASDAQ. IMO after the company goes current the share price will shoot up well above the minimum NASDAQ requirements fairly quickly and the transition will be a very swift process (generally a 4-6 week process)... Swift due to the company will be profitable enough to meet those standards easily IMO.

After reviewing the timeframe & requirements... Here are my new predictions:

2019: Financials, court case(s) resolution, USDA update, merger news (no need to be hiring currently), patents & FDA updates/approval, and NASDAQ uplist.

2020: Regular shareholders conferences, peer-reviews & media exposure, OvaDx update, company expansion worldwide following more merger announcements, further FDA updates/approvals (announcing NDA/confidential partnerships).

2021: The company will be performing drug reconciliation tests (not in the market now, but technology more than capable currently), allergy tests, food intolerance tests, ovarian cancer tests, Alzheimer’s tests, Parkinson’s disease tests, pet companions allergy tests, and possibly many more tests using the fingerstick technology.

2021/2022: The company will get acquired.

All IMO.